Next Article in Journal
Predicted Archaic 3D Genome Organization Reveals Genes Related to Head and Spinal Cord Separating Modern from Archaic Humans
Next Article in Special Issue
Structure–Function Relationship and Physiological Roles of Transient Receptor Potential Canonical (TRPC) 4 and 5 Channels
Previous Article in Journal
Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses
Previous Article in Special Issue
TRPC Channels in Proteinuric Kidney Diseases
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cells
Volume 9
Issue 1
10.3390/cells9010047
cells-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Specific Upregulation of TRPC1 and TRPC5 Channels by Mineralocorticoid Pathway in Adult Rat Ventricular Cardiomyocytes

by
Fiona Bartoli
1,
Soraya Moradi Bachiller
1,
Fabrice Antigny
2,
Kaveen Bedouet
1,
Pascale Gerbaud
1,
Jessica Sabourin
1,*,† and
Jean-Pierre Benitah
1,*,†
1
Inserm, UMR-S 1180, Signalisation et Physiopathologie Cardiovasculaire, Université Paris-Saclay, 92296 Châtenay-Malabry, France
2
Inserm, UMR-S 999, Centre Chirurgical Marie Lannelongue, Université Paris-Saclay, 92350 Le Plessis-Robinson, France
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Cells 2020, 9(1), 47; https://doi.org/10.3390/cells9010047
Submission received: 26 November 2019 / Revised: 18 December 2019 / Accepted: 22 December 2019 / Published: 23 December 2019
(This article belongs to the Special Issue TRPC Channels)
Browse Figures
Review Reports Versions Notes

Abstract

:
Whereas cardiac TRPC (transient receptor potential canonical) channels and the associated store-operated Ca2+ entry (SOCE) are abnormally elevated during cardiac hypertrophy and heart failure, the mechanism of this upregulation is not fully elucidated but might be related to the activation of the mineralocorticoid pathway. Using a combination of biochemical, Ca2+ imaging, and electrophysiological techniques, we determined the effect of 24-h aldosterone treatment on the TRPCs/Orai-dependent SOCE in adult rat ventricular cardiomyocytes (ARVMs). The 24-h aldosterone treatment (from 100 nM to 1 µM) enhanced depletion-induced Ca2+ entry in ARVMs, as assessed by a faster reduction of Fura-2 fluorescence decay upon the addition of Mn2+ and increased Fluo-4/AM fluorescence following Ca2+ store depletion. These effects were prevented by co-treatment with a specific mineralocorticoid receptor (MR) antagonist, RU-28318, and they are associated with the enhanced depletion-induced N-[4-[3,5-Bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl-1,2,3-thiadiazole-5-carboxamide (BTP2)-sensitive macroscopic current recorded by patch-clamp experiments. Molecular screening by qRT-PCR and Western blot showed a specific upregulation of TRPC1, TRPC5, and STIM1 expression at the messenger RNA (mRNA) and protein levels upon 24-h aldosterone treatment of ARVMs, corroborated by immunostaining. Our study provides evidence that the mineralocorticoid pathway specifically promotes TRPC1/TRPC5-mediated SOCE in adult rat cardiomyocytes.

1. Introduction

So far, the physiological impact of store-operated Ca2+ entry (SOCE) in adult cardiomyocytes is still under debate, notably due to low-to-moderate expression of their molecular constituents including the molecular complex of STIM1 with Orai1 channels but also with different isoforms of transient receptor potential canonical channels (TRPCs; notably 1, 4, and 5) [1,2,3,4,5]. However, there is now strong evidence revealing a role for SOCE in developmental and pathologic cardiac growth, in which Ca2+ handling regulation through Ca2+-permeable channels is a cornerstone [6,7,8,9,10,11,12]. Indeed, hardly detectable in healthy adult cardiac myocytes [13,14], SOCE is present in embryonic and neonatal cardiac myocytes [15] and re-emerges during cardiac hypertrophy and heart failure [1,3,4,16]. While it was proposed that the upregulation of cardiac SOCE during pathological growth is part of the fetal gene program [4,17], neuroendocrine factors, which underpin the pathogenesis of heart failure and trigger Ca2+-dependent processes leading to cell growth and cardiac hypertrophy, might be involved. Notably, in addition to being an Na+-retaining and kalituretic hormone that acts on the kidney, the adrenal steroid aldosterone and its classical biological effector, the mineralocorticoid receptor (MR), exert deleterious effects on cardiac function, independently of their action on blood pressure [18]. Indeed, cardiomyocytes express the MR, a ligand-dependent transcription factor interacting with the glucocorticoid-responsive elements of target genes, whose activity might control Ca2+ homeostasis on the target cells [19,20,21]. Prior studies suggested that stimulation of neonatal rat ventricular myocytes (NRVMs) or human embryonic stem-cell-derived cardiomyocytes with angiotensin II, phenylephrine, endothelin-1, or aldosterone evoked an exacerbated SOCE, correlating with increased expression of Orai1, TRPC1, TRPC4, and/or TRPC5 [11,12,22,23,24,25,26]. Arguably, primary cultures of NRVMs constitute a reliable in vitro model to study time-related myocardial cell biology but may not accurately reflect the matured adult state. Here, we showed in adult rat ventricular cardiomyocytes that the aldosterone-enhanced SOCE is associated with specific upregulation of TRPC1/C5, pointing out the necessity to corroborate data obtained in NRVMs in a mature system.

2. Material and Methods

All data and materials supporting the findings of this study are available within the article or from the corresponding authors upon reasonable request.
All experiments were carried out according to the ethical principles laid down by the French Ministry of Agriculture (agreement D-92–019-01) and were performed in accordance with the guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals. Animal studies were approved by the local Ethics Committee (CREEA Ile-de-France Sud).

2.1. Chemicals

Nifedipine (NIF) and caffeine (caf) were obtained from Sigma-Aldrich. The RU-28318, thapsigargin (Tg) and the KB-R7943 were obtained from TOCRIS Bioscience (Bristol, UK). Fluo-4/AM and Fura-2/AM were obtained from Thermo Fisher Scientific (Waltham, MA, USA).

2.2. Ventricular Myocyte Isolation

Adult rat ventricular cardiomyocytes (ARVMs) were isolated from rat hearts using a standard enzymatic perfusion method and maintained for 24 h at 37 °C in a serum-free Tyrode solution (in mM: 130 NaCl, 5.4 KCl, 0.4 NaH2PO4, 0.5 MgCl2, 25 HEPES, 22 d-glucose, 1 CaCl2; pH 7.4 with NaOH) with or without aldosterone and with or without RU28318, as previously described [19]. Only rod-shaped cells, quiescent when unstimulated and excitable, were used. In comparison to freshly isolated ARVMs, no major alterations in cellular excitability and size were noted [19,20,21,27].

2.3. Measurement of Cytosolic Ca2+ Changes

After washing, the ARVMs were incubated at room temperature in a solution containing (in mM) 135 NaCl, 5 KCl, 1.8 CaCl2, 1 MgCl2, 10 HEPES, 10 d-glucose, pH 7.4 with NaOH, supplemented either with 5 µM Fluo-4/AM (for 30 min) or with 1 μM Fura-2/AM (for 15 min). Both fluorescence probes were solved in DMSO plus 20% pluronic acid in stock solutions. The SOCE was measured as described previously [14]. The Fura-2 340/380 ratios were calibrated using the equation [Ca2+]I = KD·β·(R − Rmin)/(Rmax − R), where R is the fluorescence ratio recorded at the two excitation wavelengths (F340 and F380), KD represents the dissociation constant, Rmin and Rmax are the fluorescence ratios under Ca2+-free and Ca2+-saturating conditions, and β = F340, zero Ca2+/F380, saturating Ca2+.
For in situ measurements of Rmin and Rmax, Fura-2-loaded ARVMs were firstly exposed to Ca2+-free solution with 10 mM caf + 5 µM Tg for 5 min, to empty Sarcoplasmic Reticulum (SR) Ca2+ stores. The bath solution was then switched to K+ buffer (in mM: 10 NaCl, 130 KCl, 1 MgCl2, 10 HEPES, pH: 7.2, ionic strength: 0.142, 37 °C) containing 10 mM Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA). To obtain Rmin, the cells were incubated for 30 to 45 min with 20 µM non-fluorescent Ca2+ ionophore, ionomycin, and 10 µM carbonyl cyanide p-(trifluoromethoxy)-phenylhydrazone in K+-buffer Ca2+-free solution, and measurements were taken at both wavelengths after the fluorescence reached stable values. Then, Rmax was obtained by saturating the indicator with 10 mM or 20 mM CaCl2 in the presence of 10 mM EGTA.
To calculate the KD, a dose response (0, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, and 10.0 mM CaCl2/EGTA (free Ca2+ ranging from 0 to 37 μM)) was performed in K+ buffer. As a double-log plot, the Ca2+ response of the indicator was linear with the x-intercept equal to the log of the apparent KD of the indicator. We calculated Rmin = 0.66, Rmax = 1.84, and β = 1.35 with KD = 377 nM. Of note, aldosterone treatment did not change any parameters.

2.4. Measurement of Cation Influx Using Mn2+-Quenching of Fura-2 Fluorescence Quenching

The Mn2+ influx was measured on Fura-2/AM loaded ARVMs as described previously [11]. Fura-2 was excited at the isosbestic wavelength, 360 nm, and emission fluorescence was monitored at 510 nm. After SR depletion (see below), a 500 µM MnCl2 solution was perfused in the presence of NIF and KB-R7943, and the initial linear slope of the Fura-2 fluorescence’s decrease was measured, reflecting the SOC channel activity. The quenching rate of fluorescence intensity (F360) was estimated using linear regression of the initial decaying phase (slope, ΔF/dt) just after Mn2+ addition, expressed as a percentage decrease in F360 per min (the maximal F360 signal obtained before Mn2+ was set at 100% to correct for differences in the cell size and/or fluorophore loading). Photobleaching was <0.5%/min during measurements. All experiments were done at controlled 37 °C.

2.5. Electrophysiological Recordings

The ISOC current was recorded as described previously [11]. The SR Ca2+ stores were depleted by successive perfusion of 5 μM Tg and 10 mM caf, and then the currents (ISOC) were elicited by a 1.2-s voltage ramp from −100 mV to +60 mV, preceded by 0 to +40 mV prepulse (400 ms) to inactivate the voltage-dependent Na+ channels. The ISOC were recorded before and after 5 µM BTP2 cell perfusion, and then normalized to membrane capacitance to account for cell size variations.

2.6. Western Blot

Western blot was performed as described previously [11] using the antibodies listed in Table 1. Briefly, ARVMs were lysed in a RIPA (radioimmunoprecipitation assay) buffer. Samples were denatured in Laemmli’s buffer; then, 20–40 μg of total proteins were loaded per lane, separated on SDS-polyacrylamide gel electrophoresis, and transferred to a polyvinylidene difluoride (PVDF) membrane. Membranes were probed overnight at 4 °C with the corresponding primary antibody. After washes, the membranes were incubated with the secondary anti-rabbit, anti-mouse, or anti-rabbit IgG 1 h at room temperature. Immunoreactive bands were detected with enhanced chemiluminescent procedure using an ECL Western Blotting Analysis System. The Western blot quantification was performed with ImageJ software with normalization of target proteins to β-actin.

2.7. Immunostaining

ARVMs were fixed and permeabilized with 2% paraformaldehyde (PFA)/0.5% Triton X-100 as previously described [14]. Images were acquired using a Leica TCS SP5 confocal microscope, keeping all the acquisition parameters the same at all times. For each cell, we selected a single plane at the depth where the antibody detection was optimal. After background subtraction, as semi-quantitative analysis, the total cell fluorescence signal (integrated density) of the region of interest (ROI, by circling the cells) was normalized to the ROI area of each cell using ImageJ software (1.52d, National Institutes of Health, Bethesda, MD, USA).

2.8. Quantitative Real-Time PCR

The RNA extraction and RT-qPCR quantification were performed as previously described [11], using the primers listed in Table 2. Briefly, total RNA from ARVMs was isolated using the TRIzol procedure according to the manufacturer’s instructions. For complementary DNA (cDNA) synthesis, 1 µg of total RNA was reverse-transcribed using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA) according to the manufacturer’s instructions. Then, cDNA was used as a template for real-time PCR with SYBR Green Supermix. Quantitative determination of the different messenger RNA (mRNA) expression levels was performed with a CFX96 Touch™ Real-Time PCR Detection System with either gene-specific primers or primers for endogenous controls. The mRNA levels were normalized to housekeeping genes and were expressed as a fold change of that determined in control (ctrl) ARVMs for each isolation.

2.9. Statistical Analysis

The number of cells (n) or animals (N) studied per experiment is indicated. Statistical analyses, described in the figure legends, were performed using GraphPad Prism 6.0 software (GraphPad Software, San Diego, CA, USA). The variance assumption was automatically tested. A value of p < 0.05 was considered significant.

3. Results

3.1. Aldosterone Increases Store-Operated Ca2+ Entry (SOCE) via MR Activation in Adult Cardiomyocytes

We firstly examined the SOCE activity in quiescent rod-shaped Fluo-4/AM-loaded ARVMs, which were treated with or without aldosterone (Aldo) for 24 h. Of interest, 24-h aldosterone treatment did not induce cellular hypertrophy as assessed by the similar membrane capacitance of isolated ARVMs treated 24 h with or without 1 μM aldosterone (123 ± 6 vs. 120 ± 6 pF, for 23 control cells vs. 23 Aldo treated cells, respectively). As exemplified in Figure 1A, after SR depletion in a Ca2+-free solution containing thapsigargin (a SERCA inhibitor, Tg 5 µM), caffeine (an RyR2 activator, caf 10 mM), and nifedipine (an L-type Ca2+ channel blocker, NIF 10 µM), the subsequent addition of 1.8 mM Ca2+ in the presence of NIF and KB-R7943 (an Na+–Ca2+ exchanger inhibitor, KB 5 µM) induced a moderate increase of fluorescence in 69% of ctrl ARVMs (gray trace), while a stronger response was observed in a dose-dependent manner in all aldosterone-treated cells (100 nM, dark-gray trace and 1 µM, red trace). On average (Figure 1B), we denoted a 1.4-fold increase in Ca2+ entry in 1 µM aldosterone-treated ARVMs, which was prevented in co-treated ARVMs with a selective mineralocorticoid receptor (MR) antagonist RU-28318 (RU at 10 µM). Similar results were obtained using the ratiometric Fura-2/AM fluorescent probe (Figure 1C,D). To confirm those results, we used Mn2+-quenching microfluorimetry in the presence of major cardiac Ca2+ entry pathway inhibitors (NIF and KB). Figure 1E shows representative Fura-2/AM fluorescence traces after SR depletion of ARVMs treated with or without aldosterone for 24 h. The quenching rates, proportional to Mn2+ entry, were increased up to 1.5-fold after aldosterone incubation; the effect was blunted in ARVMs co-treated with 10 μM RU-28318 (Figure 1F). These data confirmed an increased cation entry after aldosterone treatment, which was dependent on MR activation.
To further explore the nature of the SOCE modulated by the aldosterone pathway, we recorded the store-dependent currents using the patch-clamp technique in whole-cell configuration, using solutions to limit Ca2+ and K+ currents by including inhibitors (NIF and KB) and Cs+ to block K+ channels. After SR Ca2+ store depletion (see above), the SOC currents (ISOC) were elicited by a standard ramp protocol before and after the perfusion of the non-selective SOC channel blocker BTP2 (5 µM). As shown in Figure 2A–C, the small BTP2-sensitive currents with a linear current density–voltage relationship and a reversal potential around 0 mV were recorded in ARVMs incubated without aldosterone. The ISOC was increased in aldosterone-treated ARVMs (Figure 2C). The feature of this aldosterone-enhanced ISOC induced by store depletion, i.e., its reversal potential around 0 mV and sensitivity to BTP2, suggested the activation of non-selective cationic channels carried by TRPCs.

3.2. Aldosterone Increases TRPC1, TRPC5, and STIM1 Protein Expression in Adult Cardiomyocytes

To assess the molecular nature of the aldosterone-increased SOCE, we investigated the effect of aldosterone treatment on the expression of different SOCE machinery actors, i.e., TRPCs and Orai1 channels and STIM proteins in ARVMs after 24 h of incubation. As assessed by Western blots (Figure 3), we observed an increased protein expression of TRPC1, TRPC5, and STIM1, without any changes in Orai1, TRPC3, TRPC4, TRPC6, STIM2, and Orai3 protein levels. Uncropped blots are presented in Figure S1 (Supplementary Materials). The increases in TRPC1, TRPC5 and STIM1 protein expressions were further tested by immunostaining of treated isolated cardiomyocytes (Figure 4). The fluorescence signal of these three proteins appeared more intense in 1 µM Aldo-treated cells than in ctrl cells and revealed a localization of TRPC1 and STIM1 at the surface membrane, while TRPC5 appeared to be present at the striated area, as previously reported [2,28,29,30]. At mRNA levels, using RT-qPCR, we observed an increased mRNA expression of TRPC1 and TRPC5 induced by 100 nM and 1 µM aldosterone treatment, whereas lower doses (10 nM) had no effect. STIM1 mRNA levels remained unchanged after 24 h of aldosterone treatment, no matter the concentration used (Figure 5).

4. Discussion

Our study was aimed at investigating the aldosterone effect on SOCE in ARVMs. Our results indicate that a 24-h treatment of high-dose aldosterone stimulates the SOCE in an MR-dependent manner, due to a specific upregulation of TRPC1, TRPC5, and STIM1.
Upregulation of the cardiac mineralocorticoid signaling pathway emerged as a key regulator involved in heart failure development and progression [31], in which Ca2+-dependent activation of transduction signaling is also important [32]. On the other hand, the re-emergence of cardiac SOCE machinery was recently shown in the heart failure pathological remodeling processes, contributing to Ca2+ prohypertrophic signaling [1,3,4]. Notably, the TRPC1 channel, which is the major isoform in whole human heart [33], is upregulated during heart failure progression and is critical for it [17,22,34,35,36,37]. Likewise, increased TRPC5 expression in human heart failure [38,39] and STIM1 elevation are linked to cardiac hypertrophy [9,40,41,42,43]. However, the mechanism regulating cardiac TRPC channels expression is not well defined. Since cardiac hypertrophy and heart failure can be viewed as a gene regulatory disorder [44], we hypothesize that MR as transcription factor might be involved in this process.
As previously reported [14], ARVMs show rather small Ca2+ entry following SR depletion, which is enhanced after aldosterone treatment. The presence of SOCE in adult ventricular cardiomyocytes first reported in 2004 [13] remains controversial. For example, the traditional protocol using only thapsigargin or cyclopiazonic acid (CPA) to block the SR Ca2+ pumps indicates that there is no or limited SOCE in normal adult ventricular cells [9,17,35,45]. However, these conditions might not sufficiently deplete the SR Ca2+ stores of quiescent adult ventricular cells [15,46], even if one might think that, in the presence of an SERCA pump inhibitor, the SR Ca2+ leak would deplete the SR [45]. Thus, when a clear SR Ca2+ depletion is observed (with ryanodine receptor activation through either stimulation or caffeine/ryanodine application), a moderated SOCE activity might be observed [11,14,47,48,49], as we show in the present study.
Reflecting previous reports in adrenal chromaffin cells [50] or coronary arteries [51] from metabolic syndrome pigs, in the mesenteric arterial smooth muscle cells of DOCA-salt hypertensive rats or in A7r5 cells [52] and in NRVMs [11], a chronic treatment of ARVMs with aldosterone potentiates SOCE, in line with the emergence of a marked BTP2-sensitive current after store depletion. This linear-shaped non-selective current, as assessed by its reversal potential near 0 mV, features reminiscent of TRPC channels [36,53,54]. Indeed, SOCE is a ubiquitous mechanism that is mediated by distinct SOC channels, ranging from the highly selective Ca2+ release-activated Ca2+ channel supported by the Orai1 channel to relatively Ca2+ non-selective SOC channels supported by TRPC channels [55]. Unlike NRVMs, in which aldosterone treatment enhances Orai1 expression [11], we did not observe an upregulation of Orai1 in ARVMs. This points out that the use of immature neonatal cardiomyocytes presenting unequivocal robust SOCE [9,10] might have limitations, thus justifying the present study. Nonetheless, aldosterone promotes an MR-specific increase in TRPC1/5 and STIM1 protein expression in ARVMs, as seen in metabolic syndrome adrenal chromaffin cells [50], in coronary arteries [51,56], and in NRVMs [11]. These are consistent with the ionic current features that we observed. Aldosterone increases STIM1 expression only at the protein level, suggesting a post-transcriptional regulation. In this way, it was demonstrated that STIM1 protein expression is regulated by the serum- and glucocorticoid-inducible kinase 1 (SGK1), an aldosterone-regulated kinase which phosphorylates Nedd4-2, leading to decreased ubiquitination and subsequent degradation of the STIM1 protein [57,58]. A number of studies, conducted in various cell models, implicated members of TRPC channels in SOC activity [59,60,61,62]. Notably, TRPC1 channels are believed to mediate the non-selective cation current and to form SOC channels as a component in human atria [63], in the mouse sinoatrial node [64], in human cardiac c-kit+ progenitor cells [65], in NRVMs [66], and in adult ventricular cardiomyocytes [36,46,67]. Similarly, TRPC5, which was found to contribute to the formation of SOCE in smooth muscle cells isolated from rabbit pial arterioles [68], contributes to SOCE in NRVMs [11,69]. In addition, STIM1, the critical constituent of SOCE, can directly bind to and activate TRPC1 and TRPC5 channels via interactions in its ezrin/radixin/moesin (ERM) domain [70,71,72,73,74,75,76].
Our findings provide direct support for the presence of STIM1, TRPC1, and TRPC5 in ARVMs and for their participation in aldosterone/MR-enhanced SOCE. Taking into account that G-protein-coupled receptor (GPCR) activation promotes TRPC1 and TRPC5 translocation to the plasma membrane in a STIM1-dependent manner [77] and the documented signaling crosstalk between cardiac MR and GPCR signaling components [78], further studies directed toward the potential of the cardiac MR-dependent TRPC channelosome upregulation in the receptor agonist (such as angiotensin II)-induced inositol 1,4,5-trisphosphate (IP3) sensitive Ca2+ store depletion remain to be performed.

Supplementary Materials

The following are available online at https://www.mdpi.com/2073-4409/9/1/47/s1.

Author Contributions

Conceptualization, J.S. and J.-P.B.; experiments, F.B., S.M.B., F.A., K.B., P.G., and J.S.; methodology, J.S. and J.-P.B; validation, J.S. and J.-P.B.; formal analysis, J.S. and J.-P.B.; writing—original draft preparation, J.S., F.B., and J.-P.B.; funding acquisition, J.S. and J.-P.B. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by research grants from INSERM, National Funding Agency for Research (ANR) (ANR-15-CE14), CORDDIM (Cardiovasculaire Obésité Rein Diabète Domaine d’Intérêt Majeur, Région Ile de France).

Acknowledgments

We thank the AnimEX platform for animal care and the Trans-Prot platform IFR141-IPSIT from the University of Paris-Sud, University of Paris-Saclay.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Collins, H.E.; Zhu-Mauldin, X.; Marchase, R.B.; Chatham, J.C. STIM1/Orai1-mediated SOCE: Current perspectives and potential roles in cardiac function and pathology. Am. J. Physiol. Heart Circ. Physiol. 2013, 305, H446–H458. [Google Scholar] [CrossRef] [Green Version]
  2. Ahmad, A.A.; Streiff, M.; Hunter, C.; Hu, Q.; Sachse, F.B. Physiological and pathophysiological role of transient receptor potential canonical channels in cardiac myocytes. Prog. Biophys. Mol. Biol. 2017, 130, 254–263. [Google Scholar] [CrossRef]
  3. Bartoli, F.; Sabourin, J. Cardiac Remodeling and Disease: Current Understanding of STIM1/Orai1-Mediated Store-Operated Ca2+ Entry in Cardiac Function and Pathology. Adv. Exp. Med. Biol. 2017, 993, 523–534. [Google Scholar] [CrossRef]
  4. Eder, P. Cardiac Remodeling and Disease: SOCE and TRPC Signaling in Cardiac Pathology. Adv. Exp. Med. Biol. 2017, 993, 505–521. [Google Scholar] [CrossRef]
  5. Freichel, M.; Berlin, M.; Schurger, A.; Mathar, I.; Bacmeister, L.; Medert, R.; Frede, W.; Marx, A.; Segin, S.; Londono, J.E.C. TRP Channels in the Heart. In Neurobiology of TRP Channels, 2nd ed.; Emir, T.L.R., Ed.; CRC Press/Taylor & Francis: Boca Raton, FL, USA, 2017; pp. 149–185. [Google Scholar] [CrossRef]
  6. Gao, H.; Wang, F.; Wang, W.; Makarewich, C.A.; Zhang, H.; Kubo, H.; Berretta, R.M.; Barr, L.A.; Molkentin, J.D.; Houser, S.R. Ca2+ influx through L-type Ca2+ channels and transient receptor potential channels activates pathological hypertrophy signaling. J. Mol. Cell Cardiol. 2012, 53, 657–667. [Google Scholar] [CrossRef] [Green Version]
  7. Huang, J.; van Breemen, C.; Kuo, K.H.; Hove-Madsen, L.; Tibbits, G.F. Store-operated Ca2+ entry modulates sarcoplasmic reticulum Ca2+ loading in neonatal rabbit cardiac ventricular myocytes. Am. J. Physiol. Cell Physiol. 2006, 290, C1572–C1582. [Google Scholar] [CrossRef] [Green Version]
  8. Hunton, D.L.; Lucchesi, P.A.; Pang, Y.; Cheng, X.; Dell’Italia, L.J.; Marchase, R.B. Capacitative calcium entry contributes to nuclear factor of activated T-cells nuclear translocation and hypertrophy in cardiomyocytes. J. Biol. Chem. 2002, 277, 14266–14273. [Google Scholar] [CrossRef] [Green Version]
  9. Luo, X.; Hojayev, B.; Jiang, N.; Wang, Z.V.; Tandan, S.; Rakalin, A.; Rothermel, B.A.; Gillette, T.G.; Hill, J.A. STIM1-dependent store-operated Ca2+ entry is required for pathological cardiac hypertrophy. J. Mol. Cell Cardiol. 2012, 52, 136–147. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  10. Pang, Y.; Hunton, D.L.; Bounelis, P.; Marchase, R.B. Hyperglycemia inhibits capacitative calcium entry and hypertrophy in neonatal cardiomyocytes. Diabetes 2002, 51, 3461–3467. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Sabourin, J.; Bartoli, F.; Antigny, F.; Gomez, A.M.; Benitah, J.P. Transient Receptor Potential Canonical (TRPC)/Orai1-dependent Store-operated Ca2+ Channels: NEW TARGETS OF ALDOSTERONE IN CARDIOMYOCYTES. J. Biol. Chem. 2016, 291, 13394–13409. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Voelkers, M.; Salz, M.; Herzog, N.; Frank, D.; Dolatabadi, N.; Frey, N.; Gude, N.; Friedrich, O.; Koch, W.J.; Katus, H.A.; et al. Orai1 and Stim1 regulate normal and hypertrophic growth in cardiomyocytes. J. Mol. Cell Cardiol. 2010, 48, 1329–1334. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Hunton, D.L.; Zou, L.; Pang, Y.; Marchase, R.B. Adult rat cardiomyocytes exhibit capacitative calcium entry. Am. J. Physiol. Heart Circ. Physiol. 2004, 286, H1124–H1132. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Dominguez-Rodriguez, A.; Ruiz-Hurtado, G.; Sabourin, J.; Gomez, A.M.; Alvarez, J.L.; Benitah, J.P. Proarrhythmic effect of sustained EPAC activation on TRPC3/4 in rat ventricular cardiomyocytes. J. Mol. Cell Cardiol. 2015, 87, 74–78. [Google Scholar] [CrossRef] [PubMed]
  15. Uehara, A.; Yasukochi, M.; Imanaga, I.; Nishi, M.; Takeshima, H. Store-operated Ca2+ entry uncoupled with ryanodine receptor and junctional membrane complex in heart muscle cells. Cell Calcium. 2002, 31, 89–96. [Google Scholar] [CrossRef] [PubMed]
  16. Falcon, D.; Galeano-Otero, I.; Calderon-Sanchez, E.; Del Toro, R.; Martin-Bornez, M.; Rosado, J.A.; Hmadcha, A.; Smani, T. TRP Channels: Current Perspectives in the Adverse Cardiac Remodeling. Front. Physiol. 2019, 10, 159. [Google Scholar] [CrossRef] [PubMed]
  17. Wu, X.; Eder, P.; Chang, B.; Molkentin, J.D. TRPC channels are necessary mediators of pathologic cardiac hypertrophy. Proc. Natl. Acad. Sci. USA 2010, 107, 7000–7005. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  18. Jaisser, F.; Farman, N. Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology. Pharmacol. Rev. 2016, 68, 49–75. [Google Scholar] [CrossRef] [Green Version]
  19. Benitah, J.P.; Vassort, G. Aldosterone upregulates Ca2+ current in adult rat cardiomyocytes. Circ. Res. 1999, 85, 1139–1145. [Google Scholar] [CrossRef] [Green Version]
  20. Gomez, A.M.; Rueda, A.; Sainte-Marie, Y.; Pereira, L.; Zissimopoulos, S.; Zhu, X.; Schaub, R.; Perrier, E.; Perrier, R.; Latouche, C.; et al. Mineralocorticoid modulation of cardiac ryanodine receptor activity is associated with downregulation of FK506-binding proteins. Circulation 2009, 119, 2179–2187. [Google Scholar] [CrossRef] [Green Version]
  21. Benitah, J.P.; Perrier, E.; Gomez, A.M.; Vassort, G. Effects of aldosterone on transient outward K+ current density in rat ventricular myocytes. J. Physiol. 2001, 537, 151–160. [Google Scholar] [CrossRef]
  22. Ohba, T.; Watanabe, H.; Murakami, M.; Takahashi, Y.; Iino, K.; Kuromitsu, S.; Mori, Y.; Ono, K.; Iijima, T.; Ito, H. Upregulation of TRPC1 in the development of cardiac hypertrophy. J. Mol. Cell Cardiol. 2007, 42, 498–507. [Google Scholar] [CrossRef] [PubMed]
  23. Wang, Y.; Li, Z.C.; Zhang, P.; Poon, E.; Kong, C.W.; Boheler, K.R.; Huang, Y.; Li, R.A.; Yao, X. Nitric Oxide-cGMP-PKG Pathway Acts on Orai1 to Inhibit the Hypertrophy of Human Embryonic Stem Cell-Derived Cardiomyocytes. Stem Cells 2015, 33, 2973–2984. [Google Scholar] [CrossRef] [PubMed]
  24. Kirschmer, N.; Bandleon, S.; von Ehrlich-Treuenstatt, V.; Hartmann, S.; Schaaf, A.; Lamprecht, A.K.; Miranda-Laferte, E.; Langsenlehner, T.; Ritter, O.; Eder, P. TRPC4alpha and TRPC4beta Similarly Affect Neonatal Cardiomyocyte Survival during Chronic GPCR Stimulation. PLoS ONE 2016, 11, e0168446. [Google Scholar] [CrossRef] [PubMed]
  25. Kiso, H.; Ohba, T.; Iino, K.; Sato, K.; Terata, Y.; Murakami, M.; Ono, K.; Watanabe, H.; Ito, H. Sildenafil prevents the up-regulation of transient receptor potential canonical channels in the development of cardiomyocyte hypertrophy. Biochem. Biophys. Res. Commun. 2013, 436, 514–518. [Google Scholar] [CrossRef] [Green Version]
  26. Ji, Y.; Guo, X.; Zhang, Z.; Huang, Z.; Zhu, J.; Chen, Q.H.; Gui, L. CaMKIIdelta meditates phenylephrine induced cardiomyocyte hypertrophy through store-operated Ca2+ entry. Cardiovasc. Pathol. 2017, 27, 9–17. [Google Scholar] [CrossRef] [PubMed]
  27. Perrier, E.; Perrier, R.; Richard, S.; Benitah, J.P. Ca2+ controls functional expression of the cardiac K+ transient outward current via the calcineurin pathway. J. Biol. Chem. 2004, 279, 40634–40639. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Huang, H.; Wang, W.; Liu, P.; Jiang, Y.; Zhao, Y.; Wei, H.; Niu, W. TRPC1 expression and distribution in rat hearts. Eur. J. Histochem. 2009, 53, e26. [Google Scholar] [CrossRef] [Green Version]
  29. Kojima, A.; Kitagawa, H.; Omatsu-Kanbe, M.; Matsuura, H.; Nosaka, S. Ca2+ paradox injury mediated through TRPC channels in mouse ventricular myocytes. Br. J. Pharm. 2010, 161, 1734–1750. [Google Scholar] [CrossRef] [Green Version]
  30. Jiang, Y.; Huang, H.; Liu, P.; Wei, H.; Zhao, H.; Feng, Y.; Wang, W.; Niu, W. Expression and localization of TRPC proteins in rat ventricular myocytes at various developmental stages. Cell Tissue Res. 2014, 355, 201–212. [Google Scholar] [CrossRef]
  31. Buonafine, M.; Bonnard, B.; Jaisser, F. Mineralocorticoid Receptor and Cardiovascular Disease. Am. J. Hypertens 2018, 31, 1165–1174. [Google Scholar] [CrossRef]
  32. Gravez, B.; Tarjus, A.; Jaisser, F. Mineralocorticoid receptor and cardiac arrhythmia. Clin. Exp. Pharm. Physiol. 2013, 40, 910–915. [Google Scholar] [CrossRef] [PubMed]
  33. Riccio, A.; Medhurst, A.D.; Mattei, C.; Kelsell, R.E.; Calver, A.R.; Randall, A.D.; Benham, C.D.; Pangalos, M.N. mRNA distribution analysis of human TRPC family in CNS and peripheral tissues. Brain Res. Mol. Brain Res. 2002, 109, 95–104. [Google Scholar] [CrossRef]
  34. Vindis, C.; D’Angelo, R.; Mucher, E.; Negre-Salvayre, A.; Parini, A.; Mialet-Perez, J. Essential role of TRPC1 channels in cardiomyoblasts hypertrophy mediated by 5-HT2A serotonin receptors. Biochem. Biophys. Res. Commun. 2010, 391, 979–983. [Google Scholar] [CrossRef] [PubMed]
  35. Makarewich, C.A.; Zhang, H.; Davis, J.; Correll, R.N.; Trappanese, D.M.; Hoffman, N.E.; Troupes, C.D.; Berretta, R.M.; Kubo, H.; Madesh, M.; et al. Transient receptor potential channels contribute to pathological structural and functional remodeling after myocardial infarction. Circ. Res. 2014, 115, 567–580. [Google Scholar] [CrossRef] [Green Version]
  36. Seth, M.; Zhang, Z.S.; Mao, L.; Graham, V.; Burch, J.; Stiber, J.; Tsiokas, L.; Winn, M.; Abramowitz, J.; Rockman, H.A.; et al. TRPC1 channels are critical for hypertrophic signaling in the heart. Circ. Res. 2009, 105, 1023–1030. [Google Scholar] [CrossRef]
  37. Camacho Londono, J.E.; Tian, Q.; Hammer, K.; Schroder, L.; Camacho Londono, J.; Reil, J.C.; He, T.; Oberhofer, M.; Mannebach, S.; Mathar, I.; et al. A background Ca2+ entry pathway mediated by TRPC1/TRPC4 is critical for development of pathological cardiac remodelling. Eur. Heart J. 2015, 36, 2257–2266. [Google Scholar] [CrossRef] [Green Version]
  38. Bush, E.W.; Hood, D.B.; Papst, P.J.; Chapo, J.A.; Minobe, W.; Bristow, M.R.; Olson, E.N.; McKinsey, T.A. Canonical transient receptor potential channels promote cardiomyocyte hypertrophy through activation of calcineurin signaling. J. Biol. Chem. 2006, 281, 33487–33496. [Google Scholar] [CrossRef] [Green Version]
  39. Dragun, M.; Gazova, A.; Kyselovic, J.; Hulman, M.; Matus, M. TRP Channels Expression Profile in Human End-Stage Heart Failure. Medicina 2019, 55, 380. [Google Scholar] [CrossRef] [Green Version]
  40. Correll, R.N.; Goonasekera, S.A.; van Berlo, J.H.; Burr, A.R.; Accornero, F.; Zhang, H.; Makarewich, C.A.; York, A.J.; Sargent, M.A.; Chen, X.; et al. STIM1 elevation in the heart results in aberrant Ca2+ handling and cardiomyopathy. J. Mol. Cell Cardiol. 2015, 87, 38–47. [Google Scholar] [CrossRef] [Green Version]
  41. Troupes, C.D.; Wallner, M.; Borghetti, G.; Zhang, C.; Mohsin, S.; von Lewinski, D.; Berretta, R.M.; Kubo, H.; Chen, X.; Soboloff, J.; et al. Role of STIM1 (Stromal Interaction Molecule 1) in Hypertrophy-Related Contractile Dysfunction. Circ. Res. 2017, 121, 125–136. [Google Scholar] [CrossRef]
  42. Hulot, J.S.; Fauconnier, J.; Ramanujam, D.; Chaanine, A.; Aubart, F.; Sassi, Y.; Merkle, S.; Cazorla, O.; Ouille, A.; Dupuis, M.; et al. Critical role for stromal interaction molecule 1 in cardiac hypertrophy. Circulation 2011, 124, 796–805. [Google Scholar] [CrossRef] [PubMed]
  43. Benard, L.; Oh, J.G.; Cacheux, M.; Lee, A.; Nonnenmacher, M.; Matasic, D.S.; Kohlbrenner, E.; Kho, C.; Pavoine, C.; Hajjar, R.J.; et al. Cardiac Stim1 Silencing Impairs Adaptive Hypertrophy and Promotes Heart Failure Through Inactivation of mTORC2/Akt Signaling. Circulation 2016, 133, 1458–1471. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Kohli, S.; Ahuja, S.; Rani, V. Transcription factors in heart: Promising therapeutic targets in cardiac hypertrophy. Curr. Cardiol. Rev. 2011, 7, 262–271. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Zhang, H.; Sun, A.Y.; Kim, J.J.; Graham, V.; Finch, E.A.; Nepliouev, I.; Zhao, G.; Li, T.; Lederer, W.J.; Stiber, J.A.; et al. STIM1-Ca2+ signaling modulates automaticity of the mouse sinoatrial node. Proc. Natl. Acad. Sci. USA 2015, 112, E5618–E5627. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Wen, H.; Zhao, Z.; Fefelova, N.; Xie, L.H. Potential Arrhythmogenic Role of TRPC Channels and Store-Operated Calcium Entry Mechanism in Mouse Ventricular Myocytes. Front. Physiol. 2018, 9, 1785. [Google Scholar] [CrossRef] [PubMed]
  47. Bonilla, I.M.; Belevych, A.E.; Baine, S.; Stepanov, A.; Mezache, L.; Bodnar, T.; Liu, B.; Volpe, P.; Priori, S.; Weisleder, N.; et al. Enhancement of Cardiac Store Operated Calcium Entry (SOCE) within Novel Intercalated Disk Microdomains in Arrhythmic Disease. Sci. Rep. 2019, 9, 10179. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Touchberry, C.D.; Elmore, C.J.; Nguyen, T.M.; Andresen, J.J.; Zhao, X.; Orange, M.; Weisleder, N.; Brotto, M.; Claycomb, W.C.; Wacker, M.J. Store-operated calcium entry is present in HL-1 cardiomyocytes and contributes to resting calcium. Biochem. Biophys. Res. Commun. 2011, 416, 45–50. [Google Scholar] [CrossRef] [Green Version]
  49. Wester, M.; Heller, A.; Gruber, M.; Maier, L.S.; Schach, C.; Wagner, S. Glucocorticoid stimulation increases cardiac contractility by SGK1-dependent SOCE-activation in rat cardiac myocytes. PLoS ONE 2019, 14, e0222341. [Google Scholar] [CrossRef] [Green Version]
  50. Hu, G.; Oboukhova, E.A.; Kumar, S.; Sturek, M.; Obukhov, A.G. Canonical transient receptor potential channels expression is elevated in a porcine model of metabolic syndrome. Mol. Endocrinol. 2009, 23, 689–699. [Google Scholar] [CrossRef] [Green Version]
  51. Li, W.; Chen, X.; Riley, A.M.; Hiett, S.C.; Temm, C.J.; Beli, E.; Long, X.; Chakraborty, S.; Alloosh, M.; White, F.A.; et al. Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs. Basic Res. Cardiol. 2017, 112, 54. [Google Scholar] [CrossRef]
  52. Bae, Y.M.; Kim, A.; Lee, Y.J.; Lim, W.; Noh, Y.H.; Kim, E.J.; Kim, J.; Kim, T.K.; Park, S.W.; Kim, B.; et al. Enhancement of receptor-operated cation current and TRPC6 expression in arterial smooth muscle cells of deoxycorticosterone acetate-salt hypertensive rats. J. Hypertens 2007, 25, 809–817. [Google Scholar] [CrossRef] [PubMed]
  53. Cheng, K.T.; Ong, H.L.; Liu, X.; Ambudkar, I.S. Contribution and regulation of TRPC channels in store-operated Ca2+ entry. Curr. Top. Membr. 2013, 71, 149–179. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Alvarez, J.; Coulombe, A.; Cazorla, O.; Ugur, M.; Rauzier, J.M.; Magyar, J.; Mathieu, E.L.; Boulay, G.; Souto, R.; Bideaux, P.; et al. ATP/UTP activate cation-permeable channels with TRPC3/7 properties in rat cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 2008, 295, H21–H28. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Ong, H.L.; Cheng, K.T.; Liu, X.; Bandyopadhyay, B.C.; Paria, B.C.; Soboloff, J.; Pani, B.; Gwack, Y.; Srikanth, S.; Singh, B.B.; et al. Dynamic assembly of TRPC1-STIM1-Orai1 ternary complex is involved in store-operated calcium influx. Evidence for similarities in store-operated and calcium release-activated calcium channel components. J. Biol. Chem. 2007, 282, 9105–9116. [Google Scholar] [CrossRef] [Green Version]
  56. Edwards, J.M.; Neeb, Z.P.; Alloosh, M.A.; Long, X.; Bratz, I.N.; Peller, C.R.; Byrd, J.P.; Kumar, S.; Obukhov, A.G.; Sturek, M. Exercise training decreases store-operated Ca2+entry associated with metabolic syndrome and coronary atherosclerosis. Cardiovasc. Res. 2010, 85, 631–640. [Google Scholar] [CrossRef]
  57. Eylenstein, A.; Gehring, E.M.; Heise, N.; Shumilina, E.; Schmidt, S.; Szteyn, K.; Munzer, P.; Nurbaeva, M.K.; Eichenmuller, M.; Tyan, L.; et al. Stimulation of Ca2+-channel Orai1/STIM1 by serum- and glucocorticoid-inducible kinase 1 (SGK1). FASEB J. 2011, 25, 2012–2021. [Google Scholar] [CrossRef] [Green Version]
  58. Lang, F.; Eylenstein, A.; Shumilina, E. Regulation of Orai1/STIM1 by the kinases SGK1 and AMPK. Cell Calcium 2012, 52, 347–354. [Google Scholar] [CrossRef]
  59. Sabourin, J.; Lamiche, C.; Vandebrouck, A.; Magaud, C.; Rivet, J.; Cognard, C.; Bourmeyster, N.; Constantin, B. Regulation of TRPC1 and TRPC4 cation channels requires an alpha1-syntrophin-dependent complex in skeletal mouse myotubes. J. Biol. Chem. 2009, 284, 36248–36261. [Google Scholar] [CrossRef] [Green Version]
  60. Ma, H.T.; Peng, Z.; Hiragun, T.; Iwaki, S.; Gilfillan, A.M.; Beaven, M.A. Canonical transient receptor potential 5 channel in conjunction with Orai1 and STIM1 allows Sr2+ entry, optimal influx of Ca2+, and degranulation in a rat mast cell line. J. Immunol. 2008, 180, 2233–2239. [Google Scholar] [CrossRef] [Green Version]
  61. Shi, J.; Miralles, F.; Kinet, J.P.; Birnbaumer, L.; Large, W.A.; Albert, A.P. Evidence that Orai1 does not contribute to store-operated TRPC1 channels in vascular smooth muscle cells. Channels 2017, 11, 329–339. [Google Scholar] [CrossRef] [Green Version]
  62. Saleh, S.N.; Albert, A.P.; Peppiatt-Wildman, C.M.; Large, W.A. Diverse properties of store-operated TRPC channels activated by protein kinase C in vascular myocytes. J. Physiol. 2008, 586, 2463–2476. [Google Scholar] [CrossRef] [PubMed]
  63. Zhang, Y.H.; Wu, H.J.; Che, H.; Sun, H.Y.; Cheng, L.C.; Li, X.; Au, W.K.; Tse, H.F.; Li, G.R. Functional transient receptor potential canonical type 1 channels in human atrial myocytes. Pflug. Arch. 2013, 465, 1439–1449. [Google Scholar] [CrossRef] [PubMed]
  64. Ju, Y.K.; Chu, Y.; Chaulet, H.; Lai, D.; Gervasio, O.L.; Graham, R.M.; Cannell, M.B.; Allen, D.G. Store-operated Ca2+ influx and expression of TRPC genes in mouse sinoatrial node. Circ. Res. 2007, 100, 1605–1614. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Che, H.; Li, G.; Sun, H.Y.; Xiao, G.S.; Wang, Y.; Li, G.R. Roles of store-operated Ca2+ channels in regulating cell cycling and migration of human cardiac c-kit+ progenitor cells. Am. J. Physiol. Heart Circ. Physiol. 2015, 309, H1772–H1781. [Google Scholar] [CrossRef] [Green Version]
  66. Ohba, T.; Watanabe, H.; Murakami, M.; Sato, T.; Ono, K.; Ito, H. Essential role of STIM1 in the development of cardiomyocyte hypertrophy. Biochem. Biophys. Res. Commun. 2009, 389, 172–176. [Google Scholar] [CrossRef]
  67. Ohba, T.; Watanabe, H.; Murakami, M.; Iino, K.; Adachi, T.; Baba, Y.; Kurosaki, T.; Ono, K.; Ito, H. Stromal interaction molecule 1 haploinsufficiency causes maladaptive response to pressure overload. PLoS ONE 2017, 12, e0187950. [Google Scholar] [CrossRef] [Green Version]
  68. Xu, S.Z.; Boulay, G.; Flemming, R.; Beech, D.J. E3-targeted anti-TRPC5 antibody inhibits store-operated calcium entry in freshly isolated pial arterioles. Am. J. Physiol. Heart Circ. Physiol. 2006, 291, H2653–H2659. [Google Scholar] [CrossRef] [Green Version]
  69. Dominguez-Rodriguez, A.; Mayoral-Gonzalez, I.; Avila-Medina, J.; de Rojas-de Pedro, E.S.; Calderon-Sanchez, E.; Diaz, I.; Hmadcha, A.; Castellano, A.; Rosado, J.A.; Benitah, J.P.; et al. Urocortin-2 Prevents Dysregulation of Ca(2+) Homeostasis and Improves Early Cardiac Remodeling After Ischemia and Reperfusion. Front. Physiol. 2018, 9, 813. [Google Scholar] [CrossRef] [Green Version]
  70. Asanov, A.; Sampieri, A.; Moreno, C.; Pacheco, J.; Salgado, A.; Sherry, R.; Vaca, L. Combined single channel and single molecule detection identifies subunit composition of STIM1-activated transient receptor potential canonical (TRPC) channels. Cell Calcium 2015, 57, 1–13. [Google Scholar] [CrossRef]
  71. Lee, K.P.; Choi, S.; Hong, J.H.; Ahuja, M.; Graham, S.; Ma, R.; So, I.; Shin, D.M.; Muallem, S.; Yuan, J.P. Molecular determinants mediating gating of Transient Receptor Potential Canonical (TRPC) channels by stromal interaction molecule 1 (STIM1). J. Biol. Chem. 2014, 289, 6372–6382. [Google Scholar] [CrossRef] [Green Version]
  72. Worley, P.F.; Zeng, W.; Huang, G.N.; Yuan, J.P.; Kim, J.Y.; Lee, M.G.; Muallem, S. TRPC channels as STIM1-regulated store-operated channels. Cell Calcium 2007, 42, 205–211. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  73. Yuan, J.P.; Zeng, W.; Huang, G.N.; Worley, P.F.; Muallem, S. STIM1 heteromultimerizes TRPC channels to determine their function as store-operated channels. Nat. Cell Biol. 2007, 9, 636–645. [Google Scholar] [CrossRef] [PubMed]
  74. Zeng, W.; Yuan, J.P.; Kim, M.S.; Choi, Y.J.; Huang, G.N.; Worley, P.F.; Muallem, S. STIM1 gates TRPC channels, but not Orai1, by electrostatic interaction. Mol. Cell 2008, 32, 439–448. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. Alicia, S.; Angelica, Z.; Carlos, S.; Alfonso, S.; Vaca, L. STIM1 converts TRPC1 from a receptor-operated to a store-operated channel: Moving TRPC1 in and out of lipid rafts. Cell Calcium 2008, 44, 479–491. [Google Scholar] [CrossRef] [PubMed]
  76. Sabourin, J.; Le Gal, L.; Saurwein, L.; Haefliger, J.A.; Raddatz, E.; Allagnat, F. Store-operated Ca2+ Entry Mediated by Orai1 and TRPC1 Participates to Insulin Secretion in Rat beta-Cells. J. Biol. Chem. 2015, 290, 30530–30539. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  77. Harada, K.; Matsuoka, H.; Inoue, M. STIM1-dependent membrane insertion of heteromeric TRPC1-TRPC4 channels in response to muscarinic receptor stimulation. J. Cell Sci. 2019, 132. [Google Scholar] [CrossRef] [Green Version]
  78. Parker, B.M.; Wertz, S.L.; Pollard, C.M.; Desimine, V.L.; Maning, J.; McCrink, K.A.; Lymperopoulos, A. Novel Insights into the Crosstalk between Mineralocorticoid Receptor and G Protein-Coupled Receptors in Heart Adverse Remodeling and Disease. Int. J. Mol. Sci. 2018, 19, 3764. [Google Scholar] [CrossRef] [Green Version]
Cells 09 00047 g001 550
Figure 1. A 24-h aldosterone treatment increases store-operated Ca2+ entry (SOCE) in adult rat ventricular cardiomyocytes (ARVMs). (A) Representative traces of fluorescence variation in Fluo-4/AM-loaded ARVMs pre-incubated in the absence (control (ctrl), gray trace) and in the presence of aldosterone (Aldo, 100 nM, dark-gray trace or 1 µM, red trace). Cells were exposed to 5 µM thapsigargin (Tg) plus 10 mM caffeine (caf) in the presence of 10 µM nifedipine (NIF) in Ca2+-free medium to deplete the SR and then to Ca2+-containing solution in the presence of 5 µM of KB-R7943 and NIF to evaluate the SOCE. (B) Averaged amplitude of SOCE (F/F0) in ARVMs incubated for 24 h in the absence (ctrl, white symbols) or in the presence of aldosterone (100 nM, gray symbols or 1 µM, red symbols) without or with 10 µM of the selective MR antagonist RU-28318 (RU, orange symbols in aldosterone condition and pink symbols in ctrl condition). Average results of 8–32 cells from three isolations. (C) Representative traces of [Ca2+]i variation (in nM) in Fura-2/AM-loaded ARVMs incubated for 24 h in the absence (ctrl, gray trace) or in the presence of aldosterone (100 nM, dark-gray trace; 1 µM, red trace). Fura-2/AM fluorescence 340/380 ratios were converted to [Ca2+]i as described in the methods. (D) Quantitative assessment of SOCE (in nM) from untreated (ctrl, white symbols) and 100 nM (gray symbols) or 1 µM (red symbols) aldosterone-treated cells. Average results of 24–48 cells from four isolations. (E) Representative traces of Mn2+-induced Fura-2/AM fluorescence decay in ARVMs incubated in the absence of aldosterone (ctrl) are shown in gray traces, and those in the presence of aldosterone 100 nM or 1 µM are shown in dark-gray and red traces, respectively. (F) Bar graph of the initial slope of the Mn2+-induced decrease of Fura-2/AM fluorescence fitted by linear regression and averaged (ΔF/dt, %/min) for ARVMs incubated for 24 h in the absence (ctrl, white symbols) or in the presence of aldosterone (100 nM, dark-gray symbols or 1 µM, red symbols) without or with 10 µM RU (orange symbols in aldosterone condition and pink symbols in ctrl condition). Average results of 11–25 cells from three isolations. Results are presented with scatter plots with mean ± standard error of the mean (SEM). Statistical significance was evaluated using one-way ANOVA followed by post hoc Fisher least significant difference (LSD) test for multiple comparisons. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. ctrl; # p < 0.05 vs. aldosterone.
Figure 1. A 24-h aldosterone treatment increases store-operated Ca2+ entry (SOCE) in adult rat ventricular cardiomyocytes (ARVMs). (A) Representative traces of fluorescence variation in Fluo-4/AM-loaded ARVMs pre-incubated in the absence (control (ctrl), gray trace) and in the presence of aldosterone (Aldo, 100 nM, dark-gray trace or 1 µM, red trace). Cells were exposed to 5 µM thapsigargin (Tg) plus 10 mM caffeine (caf) in the presence of 10 µM nifedipine (NIF) in Ca2+-free medium to deplete the SR and then to Ca2+-containing solution in the presence of 5 µM of KB-R7943 and NIF to evaluate the SOCE. (B) Averaged amplitude of SOCE (F/F0) in ARVMs incubated for 24 h in the absence (ctrl, white symbols) or in the presence of aldosterone (100 nM, gray symbols or 1 µM, red symbols) without or with 10 µM of the selective MR antagonist RU-28318 (RU, orange symbols in aldosterone condition and pink symbols in ctrl condition). Average results of 8–32 cells from three isolations. (C) Representative traces of [Ca2+]i variation (in nM) in Fura-2/AM-loaded ARVMs incubated for 24 h in the absence (ctrl, gray trace) or in the presence of aldosterone (100 nM, dark-gray trace; 1 µM, red trace). Fura-2/AM fluorescence 340/380 ratios were converted to [Ca2+]i as described in the methods. (D) Quantitative assessment of SOCE (in nM) from untreated (ctrl, white symbols) and 100 nM (gray symbols) or 1 µM (red symbols) aldosterone-treated cells. Average results of 24–48 cells from four isolations. (E) Representative traces of Mn2+-induced Fura-2/AM fluorescence decay in ARVMs incubated in the absence of aldosterone (ctrl) are shown in gray traces, and those in the presence of aldosterone 100 nM or 1 µM are shown in dark-gray and red traces, respectively. (F) Bar graph of the initial slope of the Mn2+-induced decrease of Fura-2/AM fluorescence fitted by linear regression and averaged (ΔF/dt, %/min) for ARVMs incubated for 24 h in the absence (ctrl, white symbols) or in the presence of aldosterone (100 nM, dark-gray symbols or 1 µM, red symbols) without or with 10 µM RU (orange symbols in aldosterone condition and pink symbols in ctrl condition). Average results of 11–25 cells from three isolations. Results are presented with scatter plots with mean ± standard error of the mean (SEM). Statistical significance was evaluated using one-way ANOVA followed by post hoc Fisher least significant difference (LSD) test for multiple comparisons. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. ctrl; # p < 0.05 vs. aldosterone.
Cells 09 00047 g001
Cells 09 00047 g002 550
Figure 2. A 24-h aldosterone treatment increases SOC currents (ISOC) in ARVMs. (A,B) Representative current–voltage (I–V) relationships elicited by ramp voltage-clamp protocol in ARVMs incubated for 24 h without (A) or with aldosterone 1 μM (B), following SR Ca2+ depletion (black traces) and then in the presence of 5 µM BTP2 (orange traces). BTP2-sensitive (blue traces) represents the difference current. (C) Scatter plots of mean ± SEM of the BTP2-sensitive I–V relationships recorded in ARVMs incubated for 24 h without (gray trace, −0.19 ± 0.19 pA/pF at −90 mV and 0.30 ± 0.17 pA/pF at +60 mV, n = 7) or with Aldo 1 µM (red trace, −1.51 ± 0.20 pA/pF at −90 mV (p < 0.01) and 0.90 ± 0.15 pA/pF at +60 mV (p < 0.05), n = 9) from three cell isolations. Statistical significance was evaluated using Student’s t-test.
Figure 2. A 24-h aldosterone treatment increases SOC currents (ISOC) in ARVMs. (A,B) Representative current–voltage (I–V) relationships elicited by ramp voltage-clamp protocol in ARVMs incubated for 24 h without (A) or with aldosterone 1 μM (B), following SR Ca2+ depletion (black traces) and then in the presence of 5 µM BTP2 (orange traces). BTP2-sensitive (blue traces) represents the difference current. (C) Scatter plots of mean ± SEM of the BTP2-sensitive I–V relationships recorded in ARVMs incubated for 24 h without (gray trace, −0.19 ± 0.19 pA/pF at −90 mV and 0.30 ± 0.17 pA/pF at +60 mV, n = 7) or with Aldo 1 µM (red trace, −1.51 ± 0.20 pA/pF at −90 mV (p < 0.01) and 0.90 ± 0.15 pA/pF at +60 mV (p < 0.05), n = 9) from three cell isolations. Statistical significance was evaluated using Student’s t-test.
Cells 09 00047 g002
Cells 09 00047 g003 550
Figure 3. A 24-h aldosterone treatment increases transient receptor potential canonical channel 1 (TRPC1), TRPC5, and STIM1 protein expression in ARVMs. Representative Western blot (top panels) and pooled data (bottom bar graph) of TRPC1, TRPC5, STIM1, Orai1, TRPC3, TRPC4, TRPC6, STIM2, and Orai3 in ARVMs incubated for 24 h in the absence or in the presence of aldosterone (100 nM or 1 µM). Protein levels were normalized by β-actin and are expressed as fold changes of that determined in untreated ARVMs for each cell isolation. Results are presented as scatter plots with median and interquartile range. Statistical significance was evaluated using one-way ANOVA (Kruskal–Wallis) followed by post hoc Dunn’s test for multiple comparisons. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. ctrl.
Figure 3. A 24-h aldosterone treatment increases transient receptor potential canonical channel 1 (TRPC1), TRPC5, and STIM1 protein expression in ARVMs. Representative Western blot (top panels) and pooled data (bottom bar graph) of TRPC1, TRPC5, STIM1, Orai1, TRPC3, TRPC4, TRPC6, STIM2, and Orai3 in ARVMs incubated for 24 h in the absence or in the presence of aldosterone (100 nM or 1 µM). Protein levels were normalized by β-actin and are expressed as fold changes of that determined in untreated ARVMs for each cell isolation. Results are presented as scatter plots with median and interquartile range. Statistical significance was evaluated using one-way ANOVA (Kruskal–Wallis) followed by post hoc Dunn’s test for multiple comparisons. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. ctrl.
Cells 09 00047 g003
Cells 09 00047 g004 550
Figure 4. Cellular localization of TRPC1, TRPC5, and STIM1 in ARVMs. Representative immunofluorescences images (top) and quantification of TRPC1, TRPC5, and STIM1 in ARVMs incubated for 24 h in the absence or in the presence of aldosterone 1 µM. Results are expressed as relative fluorescence/cellular area (RFA). Average results of 20–39 cells from three isolations. Results are presented as scatter plots with mean ± SEM. Statistical significance was evaluated using Student’s t-test. * p < 0.05, ** p < 0.01 vs. ctrl.
Figure 4. Cellular localization of TRPC1, TRPC5, and STIM1 in ARVMs. Representative immunofluorescences images (top) and quantification of TRPC1, TRPC5, and STIM1 in ARVMs incubated for 24 h in the absence or in the presence of aldosterone 1 µM. Results are expressed as relative fluorescence/cellular area (RFA). Average results of 20–39 cells from three isolations. Results are presented as scatter plots with mean ± SEM. Statistical significance was evaluated using Student’s t-test. * p < 0.05, ** p < 0.01 vs. ctrl.
Cells 09 00047 g004
Cells 09 00047 g005 550
Figure 5. A 24-h aldosterone treatment increases TRPC1 and TRPC5 messenger RNA (mRNA) expression in ARVMs. Relative TRPC1, TRPC5, and STIM1 mRNA levels in ARVMs were incubated for 24 h in the absence or in the presence of aldosterone (Aldo 10 nM, 100 nM or 1 µM). The mRNA levels determined by qRT-PCR were normalized to housekeeping genes and are expressed as fold changes of that determined in ARVMs incubated in the absence of aldosterone for each cell isolation. Results are presented as scatter plots with median and interquartile range. Statistical significance was evaluated using one-way ANOVA (Kruskal–Wallis) followed by post hoc Dunn’s test for multiple comparisons. * p < 0.05, ** p < 0.01 vs. ctrl.
Figure 5. A 24-h aldosterone treatment increases TRPC1 and TRPC5 messenger RNA (mRNA) expression in ARVMs. Relative TRPC1, TRPC5, and STIM1 mRNA levels in ARVMs were incubated for 24 h in the absence or in the presence of aldosterone (Aldo 10 nM, 100 nM or 1 µM). The mRNA levels determined by qRT-PCR were normalized to housekeeping genes and are expressed as fold changes of that determined in ARVMs incubated in the absence of aldosterone for each cell isolation. Results are presented as scatter plots with median and interquartile range. Statistical significance was evaluated using one-way ANOVA (Kruskal–Wallis) followed by post hoc Dunn’s test for multiple comparisons. * p < 0.05, ** p < 0.01 vs. ctrl.
Cells 09 00047 g005
Table
Table 1. List of primary antibodies. TRPC—transient receptor potential canonical channel.
Table 1. List of primary antibodies. TRPC—transient receptor potential canonical channel.
ProteinHostDilutionCodeSource
TRPC1Mouse1/200SC-133076Santa Cruz
TRPC3Rabbit1/200ACC-016Alomone
TRPC4Rabbit1/200ACC-018Alomone
TRPC5Mouse1/20073-104UC Davis/NIH NeuroMab Facility
TRPC6Rabbit1/200ACC-017Alomone
Orai1Rabbit1/200O8264Sigma
Orai3Rabbit1/200ACC-065Alomone
STIM1Rabbit1/200S6197Sigma
STIM2Rabbit1/200ACC-064Alomone
β-actin HRPMouse1/30,000SC-47778Santa Cruz
Table
Table 2. List of primers used for RT-qPCR.
Table 2. List of primers used for RT-qPCR.
GeneForward (5′–3′)Reverse (5′–3′)
RPL32GCT GCT GAT GTG CAA CAA AGGG ATT GGT GAC TCT GAT GG
YWHAZAGA CGG AAG GTG CTG AGA AAGAA GCA TTG GGG ATC AAG AA
TBPAAA GAC CAT TGC ACT TCG TGGCT CCT GTG CAC ACC ATT TT
STIM1TCT CTG AGT TGG AGG ATG AGT AGACAA TAT AGG GGA GCA GAG GTA AGA
TRPC1TTC CAA AGA GCA GAA GGA CTGAGG TGC CAA TGA ACG AGT G
TRPC5TGA GTG GAA GTT TGC GAG AATGG GAC AGA AGG TGT TGT TG

Share and Cite

MDPI and ACS Style

Bartoli, F.; Moradi Bachiller, S.; Antigny, F.; Bedouet, K.; Gerbaud, P.; Sabourin, J.; Benitah, J.-P. Specific Upregulation of TRPC1 and TRPC5 Channels by Mineralocorticoid Pathway in Adult Rat Ventricular Cardiomyocytes. Cells 2020, 9, 47. https://doi.org/10.3390/cells9010047

AMA Style

Bartoli F, Moradi Bachiller S, Antigny F, Bedouet K, Gerbaud P, Sabourin J, Benitah J-P. Specific Upregulation of TRPC1 and TRPC5 Channels by Mineralocorticoid Pathway in Adult Rat Ventricular Cardiomyocytes. Cells. 2020; 9(1):47. https://doi.org/10.3390/cells9010047

Chicago/Turabian Style

Bartoli, Fiona, Soraya Moradi Bachiller, Fabrice Antigny, Kaveen Bedouet, Pascale Gerbaud, Jessica Sabourin, and Jean-Pierre Benitah. 2020. "Specific Upregulation of TRPC1 and TRPC5 Channels by Mineralocorticoid Pathway in Adult Rat Ventricular Cardiomyocytes" Cells 9, no. 1: 47. https://doi.org/10.3390/cells9010047

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop